Sources & References

About this page. This is SynquUp’s source and citation register. For every medical, legal, or coverage claim on a SynquUp Health Hub, we record the original source, publisher, and the date we checked it here — organized by hub. This page is not medical advice; it documents where our educational content comes from so you (or your own clinician) can verify it directly. Sources are checked against current, authoritative publishers — primarily federal agencies, professional medical societies, and peer-reviewed literature. Sources are added as each hub is reviewed, so this list will keep growing.

Oncology Hub

Last checked: September 11, 2026

Cancer screening recommendations

Claim on the Oncology Hub Source Published / Updated
Breast cancer screening (mammogram) U.S. Preventive Services Task Force, “Screening for Breast Cancer” — uspreventiveservicestaskforce.org Final recommendation published April 30, 2024 (JAMA). Recommends biennial screening for women ages 40–74 at average risk.
Colorectal cancer screening U.S. Preventive Services Task Force, “Screening for Colorectal Cancer” — uspreventiveservicestaskforce.org Final recommendation, May 18, 2021. Recommends screening starting at age 45 (not 50) through age 75; individualized for ages 76–85.
Cervical cancer screening (Pap / HPV) U.S. Preventive Services Task Force, “Screening for Cervical Cancer” — uspreventiveservicestaskforce.org Recommends screening ages 21–65: Pap every 3 years (21–65), or Pap+HPV co-testing every 5 years (30–65).
Lung cancer screening (low-dose CT) U.S. Preventive Services Task Force, “Screening for Lung Cancer” — uspreventiveservicestaskforce.org Final recommendation, March 9, 2021. Recommends annual screening for ages 50–80 with a 20 pack-year smoking history, current smoker or quit within 15 years.
Prostate cancer screening (PSA) U.S. Preventive Services Task Force, “Screening for Prostate Cancer” — uspreventiveservicestaskforce.org Recommends an individual, shared decision-making conversation for men ages 55–69 (C grade); recommends against routine PSA screening for men 70+ (D grade).
Most USPSTF-recommended screenings are covered with no out-of-pocket cost Section 2713, Public Health Service Act (added by the ACA); summarized by CDC and CMS/Medicaid.gov Applies to USPSTF “A” or “B” grade services in non-grandfathered private plans and Medicaid-expansion plans; coverage can vary for grandfathered plans and some state Medicaid programs.

Treatment types

Claim Source Notes
Overview of surgery, chemotherapy, radiation, immunotherapy, targeted therapy, and combination treatment National Cancer Institute, “Types of Cancer Treatment” — cancer.gov/about-cancer/treatment/types NCI is the primary federal source for consumer-facing cancer treatment education.
Treatment categories, cross-checked against clinical practice guidance National Comprehensive Cancer Network, NCCN Guidelines for Patients® (patient-friendly translations of the NCCN Clinical Practice Guidelines in Oncology) — nccn.org/patientresources NCCN is an alliance of 33 leading cancer centers; guidelines are developed by multidisciplinary expert panels and updated on an ongoing basis by cancer type.

Screening — secondary reference

Claim Source Notes
Cancer screening and early-detection guidance National Comprehensive Cancer Network, NCCN Guidelines for Patients® — Screening — nccn.org/patientresources SynquUp uses USPSTF as the primary source for screening eligibility (it sets ACA no-cost-sharing coverage); NCCN guidance is checked alongside it and used where it adds cancer-type-specific detail USPSTF doesn’t cover.

Clinical trials

Claim Source Notes
Trial participants still receive standard care; placebo alone (with no active treatment) is rare in cancer trials National Cancer Institute, “Placebos in Cancer Clinical Trials” and NCI clinical trials patient education materials — cancer.gov/about-cancer/treatment/clinical-trials When a placebo is used, it is typically added on top of standard-of-care treatment, not substituted for it, and patients are always informed in advance that a placebo may be part of the trial.
Trials are regulated, require informed consent, and participation is voluntary National Cancer Institute — cancer.gov Standard clinical trials education.

Support resources linked from this hub

Resource Publisher Used for
Seeking a Second Opinion American Cancer Society — cancer.org “Find Second Opinion” CTA (diagnosis view)
Find a Cancer Center National Cancer Institute — cancer.gov “Find Second Opinion” CTA (support view)
Road to Recovery (transportation) American Cancer Society — cancer.org “Find Rides” CTA
Caregiver resources American Cancer Society — cancer.org “Caregiver Resources” CTA
Oncology-specific mental health support CancerCare — cancercare.org “Find Support” CTA
Find a Nutrition Expert Academy of Nutrition and Dietetics — eatright.org “Find a Dietitian” CTA
Side Effects of Cancer Treatment National Cancer Institute — cancer.gov “Side Effect Library” CTA
A to Z List of Cancer Drugs National Cancer Institute — cancer.gov “Medication Guide” CTA
Talking With Your Doctor National Cancer Institute — cancer.gov “Prepare Questions” CTA

Substance Use Disorder Hub

Last checked: September 11, 2026

Claim Source Notes
Good Samaritan overdose laws exist in every state Network for Public Health Law, “Legal Interventions to Reduce Overdose Mortality: Overdose Good Samaritan Laws” (50-state survey, current as of Dec 31, 2025) — networkforphl.org; also U.S. GAO, “Drug Misuse: Most States Have Good Samaritan Laws” (GAO-21-248) All 50 states + DC now have some form of overdose Good Samaritan law (Wyoming enacted its law in 2025, the last state to do so). Protections vary significantly by state — what’s covered, whether immunity applies before or after arrest, and whether it extends to probation/parole violations all differ. Roughly 30 states still have drug-induced-homicide laws that can apply separately. We corrected site copy that had implied blanket immunity (“you cannot get in trouble”).
Buprenorphine, methadone, and naltrexone reduce overdose death risk by about 50% Standard finding in addiction medicine literature (e.g., SAMHSA, NIDA) — MOUD is associated with roughly 50% lower all-cause and overdose mortality compared with no treatment Commonly cited figure; SynquUp should replace with a direct current SAMHSA/NIDA citation on next review pass.
42 CFR Part 2 gives substance use treatment records added confidentiality protection beyond HIPAA Federal regulation, 42 CFR Part 2 (SAMHSA) — samhsa.gov Accurate as a general statement.

Sepsis Recovery Hub

Last checked: September 11, 2026

Claim Source Notes
Post-discharge antibiotic duration for sepsis-related infections Surviving Sepsis Campaign guideline (Society of Critical Care Medicine / European Society of Intensive Care Medicine), summarized in Lee & Bosch, “Antimicrobial Therapy for Sepsis” — PMC7372214 Current guidance is ~7–10 days for most serious infections associated with sepsis/septic shock (weak recommendation, low-quality evidence), individualized by source control and clinical response — can be shortened (e.g. pyelonephritis) or lengthened (e.g. undrained infection, S. aureus bacteremia) for specific cases. We corrected site copy that had stated a flat “1–4 weeks beyond discharge” as if it were a general rule; current stewardship guidance is trending toward shorter courses, not longer, to reduce antibiotic resistance and C. difficile risk.

Asthma Hub

Last checked: September 11, 2026

Claim Source Notes
How quickly an asthma attack can worsen; the green/yellow/red zone action-plan framework National Heart, Lung, and Blood Institute (NHLBI/NIH), National Asthma Education and Prevention Program — Asthma Action Plan and Red Zone guidance (aligned to the 2020 Focused Updates to the Asthma Management Guidelines) — nhlbi.nih.gov NHLBI/NAEPP is the U.S. clinical standard (not an international one) and is the actual source of the green/yellow/red zone system this hub already uses. NHLBI’s own Red Zone material describes a “sudden increase” in symptoms and instructs calling an ambulance if there’s no improvement within 15 minutes of treatment — supporting a “don’t wait” framing rather than the site’s prior “there’s usually time to act” language. International sources (e.g. Asthma Australia) independently confirm the same pattern — attacks can build gradually or escalate within minutes — but NHLBI is the citation that matters for a U.S. audience.

Oncology Hub — Clinical Trial Myths Verification (added)

Last checked: September 13, 2026

Claim Source Notes
“Am I a guinea pig?” / “Will I get a placebo?” / “Are trials only for people who’ve run out of options?” myths and their corrections ECOG-ACRIN “Myths and Facts About Cancer Clinical Trials”; Leukemia & Lymphoma Society; multiple major cancer center patient-education pages All three myth corrections confirmed accurate and consistent with current authoritative patient-education sources; no changes needed.

Oncology Hub — Treatment-Types Table Verification (added)

Last checked: September 13, 2026

Claim Source Notes
Immunotherapy description: “helps your immune system recognize and attack cancer… specific cancers (melanoma, lung, kidney, others); often newer option” MD Anderson Cancer Center patient education; 2026 Cancer Immunotherapy Month overview Confirmed current: immunotherapy is now standard care for more than a dozen adult cancers as of 2026, matching the hub’s framing without overstatement.

Oncology Hub — Burn Pit Cancer Link Verification (added)

Last checked: September 13, 2026

Claim Source Notes
Burn pit exposure “linked to respiratory and rare cancers” PACT Act presumptive burn pit cancer list (respiratory, brain, GI, head/neck, kidney, lymphoma, melanoma, pancreatic, glioblastoma, plus 9 specific rare respiratory cancer subtypes) Confirmed accurate; hub’s summary is appropriately general rather than an exhaustive list, and doesn’t overstate.

Oncology Hub — Camp Lejeune Cancer Link Verification (added)

Last checked: September 13, 2026

Claim Source Notes
Camp Lejeune’s contaminated water (1953–1987) “carries its own recognized cancer links” VA.gov Camp Lejeune presumptive conditions (current list includes kidney, liver, and bladder cancer, multiple myeloma, non-Hodgkin’s lymphoma, and adult leukemia) Hub’s generic phrasing is accurate and doesn’t overstate specifics; no correction needed.

Oncology Hub — PACT Act & Agent Orange Cancer List Verification (added)

Last checked: September 13, 2026

Claim Source Notes
Agent Orange presumptive cancer list: bladder cancer, leukemias/lymphomas, multiple myeloma, prostate cancer, respiratory cancers, soft tissue sarcomas 38 CFR 3.309(e); VA.gov Agent Orange presumptive conditions page Confirmed accurate and current, including standard sarcoma exclusions (osteosarcoma, chondrosarcoma, Kaposi’s sarcoma, mesothelioma).
PACT Act presumptive cancer list continues to expand (added a note that leukemias, multiple myeloma, and genitourinary cancers were added as recently as January 2025) VA.gov PACT Act updates; multiple 2026 VA-benefits trackers Added a currency caveat to the hub so readers don’t treat the 2022 list as static.

Oncology Hub — NCI-Designated Center Claim Verification (added)

Last checked: September 13, 2026

Claim Source Notes
NCI-designated centers described as “research-driven, often best for rare or complex cases” National Cancer Institute — cancer.gov NCI-Designated Cancer Centers Program page Confirmed 74 currently designated centers (58 Comprehensive, 8 Clinical, 8 Basic Laboratory) as of the most recent count. Framing is directionally accurate; NCI itself and outside sources note designation reflects research activity specifically, not a guarantee of superior care for every patient, and that community oncology can be the right choice for many standard-treatment cases.

Oncology Hub — Screening Coverage Claim Verification (added)

Last checked: September 13, 2026

Claim Source Notes
“Most screenings are covered by insurance with no out-of-pocket cost under the ACA” Kennedy v. Braidwood Management, U.S. Supreme Court, decided June 27, 2025 (6-3), upholding ACA Section 2713’s no-cost-sharing requirement for USPSTF A/B-graded preventive services Confirmed current and settled law as of September 13, 2026 — no changes needed.

Oncology Hub — Oxaliplatin Medication Safety Note (added)

Last checked: September 13, 2026

Claim Source Notes
Oxaliplatin drug class, FDA-approved indication (with 5-FU/leucovorin for stage III colon cancer adjuvant treatment and advanced colorectal cancer), boxed warning (hypersensitivity/anaphylaxis), contraindication, common and serious adverse reactions, bleeding-risk interaction with anticoagulants, embryo-fetal toxicity/contraception guidance, and urgent-symptom list FDA-approved oxaliplatin prescribing information, accessdata.fda.gov (Eloxatin label and generic oxaliplatin injection labels); current manufacturer prescribing information (Sanofi, Baxter) Added per the mandatory medication hard-gate standard applied to this hub September 13, 2026 — full FDA safety information provided in a dedicated callout adjacent to the existing packing-list mention, rather than only in the packing tip itself.

Oncology Hub — Transportation & Gas Card Assistance (added)

Last checked: September 13, 2026

Claim Source Notes
Gas card assistance for cancer patients is real but typically distributed locally by individual hospitals/cancer centers, often funded through American Cancer Society grants, rather than through one national program Multiple documented ACS-funded hospital gas card programs (e.g., Loma Linda University Cancer Center, Tidelands Health); CancerCare financial assistance program description Framed accurately as “ask your hospital social worker” rather than implying a single national gas-card website, since availability and funding vary significantly by location.
CancerCare’s financial assistance grants can cover transportation costs including gas CancerCare — cancercare.org/financial_assistance Verified current program description.

UTI & Recurrent Infections Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Gap closed: phenazopyridine (Pyridium, Azo) named with only “numbs pain, symptomatic only” description, no safety information FDA-approved phenazopyridine prescribing information; MSKCC and PDR patient references Full safety card added (2-day max use, G6PD/kidney precautions, urine discoloration, rare methemoglobinemia/liver risk).
Fluoroquinolone boxed warning (tendon rupture, peripheral neuropathy, CNS effects, myasthenia gravis exacerbation) FDA-approved ciprofloxacin/levofloxacin prescribing information Already accurate and complete on the hub; no changes needed.

Substance Use Disorder Hub — Additional Findings

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Gap closed: buprenorphine, methadone, and naltrexone were named with mechanism descriptions only, no FDA safety information at all FDA-approved Suboxone, Sublocade, and Vivitrol prescribing information; 2017 FDA Drug Safety Communication on MOUD and benzodiazepines Full safety cards added covering respiratory depression/benzodiazepine interaction (buprenorphine), QT prolongation (methadone), and opioid-overdose vulnerability after blockade (naltrexone) — a genuinely significant gap given this hub actively connects a vulnerable population to these medications.
Corrected: “buprenorphine, methadone, and naltrexone reduce overdose death by about 50%” incorrectly grouped naltrexone with the same mortality figure National Academies of Sciences, “Medications for Opioid Use Disorder Save Lives” (2019), citing Degenhardt et al. 2014, Larochelle et al. 2017, Sordo et al. 2017 The ~50% mortality reduction is well-established specifically for buprenorphine and methadone; naltrexone studies haven’t had sufficient power/follow-up to establish the same mortality benefit, per the National Academies review. Text corrected to reflect this distinction while still presenting naltrexone as a legitimate option.

Stroke and TIA Recovery Hub

Full audit pass completed September 13, 2026

No specific drugs named — medication table uses only classes (anticoagulants/antiplatelets, statins, BP medications), consistent with prior verification on the AFib and CAD hubs. FAST stroke recognition framework previously verified via the American Stroke Association. Clean pass, no changes needed.

Oncology Hub — Copay Foundations & Appearance Resources (added)

Last checked: September 13, 2026

Claim Source Notes
TotalAssist (merger of PAN Foundation and Patient Advocate Foundation Co-Pay Relief, launched July 1, 2026) as the nation’s largest charitable patient assistance program, plus CancerCare Co-Payment Assistance Foundation and HealthWell Foundation, as nonprofit copay assistance options including for Medicare patients where manufacturer cards don’t apply Patient Advocate Foundation / PAN Foundation merger announcement (uniting.patientadvocate.org); CancerCare, “How Co-Payment Assistance Foundations Help” (patient fact sheet); each organization’s own site (totalassist.org, cancercarecopay.org, healthwellfoundation.org) Corrected September 13, 2026: the previously separate PAN Foundation and Patient Advocate Foundation Co-Pay Relief programs merged into TotalAssist on July 1, 2026 — verified current names, URLs, and phone numbers directly against each organization’s own site.
Look Good Feel Better as a free, national program (skin/nail care, wigs, head coverings), now open to women, men, and teens Look Good Feel Better Foundation / Professional Beauty Association — lookgoodfeelbetter.org Confirmed current eligibility (expanded beyond women-only in recent years).
American Cancer Society’s tlc program for wigs, headwear, and mastectomy/prosthesis products at affordable prices, with Medicare guidance American Cancer Society — tlcdirect.org Verified current.
A wig prescribed as a “cranial prosthesis” may be covered by insurance, including some Medicare Advantage plans Standard patient-billing guidance widely used by oncology social workers and wig providers Coverage varies by plan; hub correctly frames this as something to ask about, not a guarantee.

Pneumonia Hub

Full audit pass completed September 13, 2026

Claim Source Notes
Corrected: antibiotic duration table said “5-14 days typical course,” which significantly overstates the upper end 2019 IDSA/ATS CAP guideline; 2025 European guidance and randomized trial data (Israelsen et al.); multiple 2024-2025 antibiotic stewardship studies Current guidance strongly favors 5 days for most uncomplicated cases once clinically improving, with emerging evidence supporting even 3 days for early stabilizers — parallel to the earlier Sepsis hub correction on the same theme (shorter courses, not longer, is the current stewardship direction).
No specific drugs named on this hub, only classes N/A Medication hard gate not applicable.

Preventive Care Hub

Full audit pass completed September 13, 2026

Claim Source Notes
RSV vaccine: 75+ routine, 50-74 with risk factors ACIP (2025 action lowering the risk-based threshold from 60 to 50) Confirmed accurate and current — hub already correctly reflects the 2025 update.
COVID-19 vaccine: shared clinical decision-making rather than universal recommendation, for both 65+ and under-65 ACIP 2025-2026 season recommendations Confirmed accurate and current.
PCF 2024 guideline: Black men should discuss baseline PSA testing at 40-45 rather than 50-55, given ~2x prostate cancer mortality risk Garraway et al., “Prostate Cancer Foundation Screening Guidelines for Black Men,” NEJM Evidence 2024;3(5) Confirmed exactly accurate.
No medications named on this hub N/A Medication hard gate not applicable.

Post-Discharge Recovery Hub

Full audit pass completed September 13, 2026

Claim Source Notes
7-day follow-up appointment described as “the strongest predictor” of avoiding readmission Camden Coalition JAMA Network Open study; Medicare HRRP cohort studies; heart-failure-specific follow-up studies Well-supported by extensive evidence; softened “the strongest predictor” to “one of the strongest predictors” for precision.
No medications named on this hub N/A Medication hard gate not applicable.

Pain Management & Functional Recovery Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Acetaminophen safety card (same as Osteoarthritis hub) FDA OTC labeling requirements for acetaminophen Card added independently since this hub must stand on its own.
CDC 2022 opioid guideline: non-opioid first, individualized care rather than rigid dose thresholds, gradual/shared tapering CDC 2022 Clinical Practice Guideline for Prescribing Opioids; JAMA Internal Medicine summary; STAT News Confirmed exactly accurate.
SAMHSA National Helpline: 1-800-662-4357 SAMHSA.gov official page Confirmed exactly correct.

Obesity & GLP-1 Hub — GIP Addition & Re-Audit

Updated and re-audited September 13, 2026

Claim Source Notes
Added: new table row distinguishing dual GIP/GLP-1 receptor agonists (tirzepatide/Zepbound) from GLP-1-only medications (semaglutide/Wegovy), matching the structure already used on the Diabetes hub FDA approval announcement, Zepbound (tirzepatide), November 8, 2023 — first dual GIP/GLP-1 agonist approved for chronic weight management Confirmed accurate; Zepbound approved for BMI ≥30, or ≥27 with a weight-related condition.
Dual GIP/GLP-1 agonists show “larger average weight-loss results in head-to-head studies” vs. GLP-1-only medications SURMOUNT-5 trial (NEJM, May 2025): tirzepatide 20.2% vs. semaglutide 13.7% weight loss, 47% greater relative reduction, 751 participants Confirmed exactly accurate — this is a genuine head-to-head randomized trial, not an indirect comparison.
Boxed warning heading updated to “GLP-1 and dual GIP/GLP-1 medications” for precision N/A Cosmetic/precision update; underlying safety content (already comprehensive from earlier this session) applies to both mechanisms.
BMI calculator “uses the standard NIH formula” NIH/CDC standard BMI formula: weight (lbs) ÷ height (in)² × 703 Confirmed accurate for the imperial units the calculator actually uses (feet/inches/pounds).

Combined with the medication-safety expansion done earlier this session (full pancreatitis/gallbladder/AKI/retinopathy/perioperative/pregnancy card, compounded-GLP-1 warning, eating disorder helpline verification), this hub is now fully current and complete.

Osteoarthritis Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Gap closed: acetaminophen named with no safety information FDA OTC labeling requirements for acetaminophen, accessdata.fda.gov Full safety card added (4,000mg/24hr max from all sources, liver damage risk, alcohol interaction, rare serious skin reactions).
ACR/Arthritis Foundation guidance against hyaluronic acid (strong for hip, conditional for knee/thumb) and PRP/stem cell injections (strong against for both hip and knee) 2019 ACR/Arthritis Foundation OA guideline; Rheumatology Advisor; ACR press release Confirmed exactly accurate including the specific hip/knee distinction for hyaluronic acid.

Obesity & GLP-1 Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Gap closed: existing GLP-1 boxed-warning card covered only the thyroid C-cell/MTC warning, missing pancreatitis, gallbladder disease, hypoglycemia-with-insulin risk, acute kidney injury, heart rate increase, semaglutide-specific diabetic retinopathy risk, delayed gastric emptying/perioperative aspiration risk, and pregnancy guidance FDA-approved Wegovy/Zepbound prescribing information; ASA perioperative guidance Card expanded to match the standard applied to the Diabetes hub’s GLP-1 card.
FDA has published safety/quality warnings on compounded semaglutide and tirzepatide (dosing accuracy, ingredient sourcing) FDA post-market safety communications; Becker’s Hospital Review (May 2026: 990+ semaglutide, 730+ tirzepatide adverse event reports); active FDA restriction of compounding now that both drugs are off the shortage list Confirmed accurate and very current; this remains an active, escalating regulatory situation as of 2026.
National Alliance for Eating Disorders helpline: 1-866-662-1235 Multiple corroborating sources including the organization’s own site Confirmed exactly correct (also now absorbs NEDA’s old number via redirect).

Mental Health Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Gap closed: esketamine (Spravato) was grouped with TMS and ECT as a “Brain Stimulation Therapy” without noting it’s a medication with a serious FDA boxed warning (sedation, dissociation, respiratory depression, abuse/misuse, suicidal thoughts), REMS restriction, and mandatory 2-hour post-dose monitoring FDA-approved Spravato (esketamine) prescribing information, accessdata.fda.gov Table entry corrected to distinguish the medication from the two device-based therapies; full safety card added.
Suicide risk highest in first 7 days after psychiatric hospital discharge, especially before the first follow-up appointment Multiple peer-reviewed case-control studies (Hunt et al. 2009; Bickley et al. 2013); NICE Guideline 53’s 7-day follow-up standard Confirmed accurate and consistent with the clinical literature.
Antidepressant boxed warning (increased suicidal thoughts/behavior in children, adolescents, young adults) FDA class labeling for antidepressants Confirmed accurate; already correctly worded on the hub.

Medication Management and Safety Hub

Full audit pass completed September 13, 2026

Claim Source Notes
FDA flush list examples: fentanyl patches, buprenorphine, hydrocodone, morphine, oxycodone, diazepam FDA’s official flush list, fda.gov/drugdisposal; multiple corroborating current sources Confirmed all six accurate and current. These drugs are named only in a disposal context, not treatment — no prescribing-information hard gate applies since no clinical use guidance is given.

Insurance and Medicare Hub

Full audit pass completed September 13, 2026

Claim Source Notes
Enhanced ACA subsidies expired Dec 31, 2025; 400% FPL subsidy cliff returned for 2026; income figures ($62,600 single, $128,600 family of four) CNBC (Jan 2026); Bipartisan Policy Center; Urban Institute; ASTHO; AJMC Confirmed exactly accurate and current. Added a note about pending (not yet enacted) House legislation to restore enhancements, since that’s live and relevant context the hub didn’t mention.
COBRA extendable up to 36 months “in some cases” Standard COBRA law (18 months base, up to 29 months disability extension, up to 36 months for certain qualifying events) Accurately and appropriately hedged; no correction needed.
No medications named on this hub N/A Medication hard gate not applicable.

Home Health, Hospice and Palliative Care Hub

Full audit pass completed September 13, 2026 (still DRAFT, unpublished — publish decision pending Chuck)

Claim Source Notes
Jimmo v. Sebelius (2013): Medicare skilled nursing/therapy coverage does not require improvement, only need for skilled care to maintain condition or slow decline; ongoing enforcement problems documented by Center for Medicare Advocacy Center for Medicare Advocacy case summary; CMS Jimmo factsheet; approved January 24, 2013 Confirmed exactly accurate, including the nuance that enforcement gaps persist.
VA Aid & Attendance: 90 days active duty/1 day wartime, net worth limit, primary residence up to 2 acres and vehicles excluded 38 CFR 3.275; multiple corroborating 2026 sources Confirmed accurate; corrected one small imprecision — “one vehicle” changed to “family transportation vehicles” (plural, no fixed number) per the actual regulation.
Medicare Part A SNF coinsurance: $0 days 1-20, $217/day days 21-100, nothing past day 100 (2026 figures) CMS’s own November 2025 CY2026 premium/deductible announcement Confirmed exactly correct.
No medications named anywhere in this hub (full 72,520 characters now reviewed) N/A Medication hard gate not applicable — confirmed across the entire hub.

This is an exceptionally well-researched hub overall — extensive, specific, checkable claims (Jimmo v. Sebelius, PSDA 1990, VA Aid & Attendance, Medicaid estate recovery/spousal impoverishment, Nursing Home Reform Law, current-year Medicare cost figures) were all confirmed accurate on verification, with only one minor imprecision found and fixed.

HIV & PrEP Care Hub

Full audit pass completed September 13, 2026

Claim Source Notes
Oral PrEP: ~99% effective against sexual transmission, ~74% for people who inject drugs, with consistent use HIV.gov PrEP page Confirmed exactly accurate.
Two injectable PrEP options currently available: one every 2 months, one every 6 months Gilead press release (Yeztugo/lenacapavir FDA approval, June 2025); Pharmacy Times; FDA Confirmed accurate and current — refers to Apretude (cabotegravir, every 2 months) and Yeztugo (lenacapavir, every 6 months, approved June 2025).
No specific PrEP brand/generic drug names used in the options table — described generically as “oral” and “injectable” N/A Medication hard gate not triggered by this hub.

High Blood Pressure Hub

Full audit pass completed September 13, 2026

Claim Source Notes
180/120 with symptoms (chest pain, severe headache, vision changes) = hypertensive emergency, call 911 2017 ACC/AHA hypertension guideline; multiple corroborating 2026 clinical sources Confirmed exactly accurate and still current.
No specific drugs named on this hub, only classes N/A Medication hard gate not applicable.

Heart Failure Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Spironolactone: hyperkalemia monitoring requirement, gynecomastia (~9% incidence), electrolyte disturbances, drug interactions (digoxin, lithium, NSAIDs) FDA-approved spironolactone/Aldactone prescribing information, accessdata.fda.gov; RALES trial data Full safety card added.
Eplerenone: same hyperkalemia risk, no gynecomastia, CYP3A4 interaction risk FDA-approved eplerenone/Inspra prescribing information, accessdata.fda.gov Full safety card added.
Daily weight monitoring thresholds (2-3 lbs/day, 5 lbs/week) and green/yellow/red zone framework Standard AHA/ACC heart failure self-care guidance Well-established clinical teaching; not independently re-searched this pass given high confidence, consistent with standard practice.

Healthcare Costs and Financial Assistance Hub

Full audit pass completed September 13, 2026

Claim Source Notes
CFPB medical debt credit-reporting rule finalized Jan 2025, vacated July 11, 2025, never took full effect; voluntary bureau protections (paid debt removed, under-$500 not reported, ~12-month delay) remain current CFPB.gov archive; Cornerstone Credit Union League v. CFPB (E.D. Tex., July 11, 2025); multiple corroborating 2026 legal/financial sources Confirmed precisely accurate and current — an unusually well-researched section already.
IRC Section 501(r) requiring nonprofit hospital financial assistance policies Existing, well-established federal tax law Accurate; not independently re-verified this pass but consistent with established law.
No medications named on this hub N/A Medication hard gate not applicable.

Food, Housing and Daily Help Hub

Full audit pass completed September 13, 2026

Claim Source Notes
National Domestic Violence Hotline: 1-800-799-7233, text START to 88788 Multiple corroborating 211/nonprofit directories, thehotline.org Confirmed exactly accurate and current.
No medications named on this hub N/A Medication hard gate not applicable.

Falls & Frailty Hub

Full audit pass completed September 13, 2026

Claim Source Notes
National Falls Prevention Awareness Week is September 21-25, 2026; about 1 in 4 adults 65+ falls each year NCOA official press release, September 1, 2026 Confirmed exactly accurate and current, directly from NCOA’s own announcement.
No medications named on this hub (medication review discussed only generically) N/A Medication hard gate not applicable.

Emergency Readiness Hub

Full audit pass completed September 13, 2026

Claim Source Notes
EMTALA (1986) requires Medicare-participating ERs to screen/stabilize regardless of ability to pay; some for-profit standalone ERs decline Medicare specifically to avoid this obligation CMS.gov EMTALA patient rights page; June 30, 2026 HealthDay/STAT reporting on Nutex Health (27 hospitals, 12 states, declining Medicare) Confirmed accurate and current as of a June 2026 investigative report — this is a real, active, growing practice, not a hypothetical caution.
No medications named on this hub N/A Medication hard gate not applicable.

DME, Home Safety and Rehabilitation Hub

Full audit pass completed September 13, 2026

Claim Source Notes
Medicare DME technical definition (durable, medical reason, home use, 3+ year expected life) and 80/20 coverage split after Part B deductible Medicare.gov DME coverage page; multiple corroborating sources Confirmed exactly accurate; no changes needed.
No medications named on this hub N/A Medication hard gate not applicable.

Diabetes Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Gap closed: Metformin table entry named the drug with no mention of its FDA boxed warning for lactic acidosis (fatal in ~50% of cases), or the required pre-treatment kidney testing FDA-approved metformin prescribing information, accessdata.fda.gov Full safety card added.
Gap closed: existing GLP-1 boxed-warning card covered only the thyroid C-cell/MTC warning, missing pancreatitis, gallbladder disease, hypoglycemia-with-insulin risk, acute kidney injury, heart rate increase, semaglutide-specific diabetic retinopathy risk, delayed gastric emptying/perioperative aspiration risk, and pregnancy guidance — all explicitly required by the GLP-1 hard-gate standard FDA-approved Wegovy/Ozempic/Zepbound prescribing information; ASA perioperative guidance; peer-reviewed comparative safety literature Card substantially expanded to cover all required elements.
GLP-1 vs. dual GIP/GLP-1 correctly distinguished as separate table rows with different mechanisms N/A — verified existing table structure Already compliant; no change needed.

Dementia Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Memantine (Namenda): indication (moderate-severe only), no boxed warning, adverse reactions, renal/urinary caution, rare seizure/psychiatric post-marketing reports FDA-approved Namenda/memantine prescribing information, accessdata.fda.gov Full safety card added.
Critical gap closed: “Disease-modifying therapies” table entry said only “modestly slows progression… requires monitoring” with no mention of the FDA boxed warning for ARIA (brain swelling/bleeding, 20-35%+ incidence, occasionally fatal) carried by Leqembi (lecanemab) and Kisunla (donanemab) FDA-approved Leqembi and Kisunla prescribing information, accessdata.fda.gov; UCLA Easton Center for Alzheimer’s Research patient education Table entry corrected and full safety card added naming both drugs specifically, since “requires monitoring” without explaining why significantly understated the risk.

Coronary Artery Disease Hub

Full audit pass completed September 13, 2026

Claim Source Notes
DAPT early discontinuation risk of stent thrombosis, including around dental/minor procedures Multi-society advisory (ACC/AHA and others); ACC/AHA 2016 DAPT guideline update Confirmed accurate and consistent with current guidance; 6-12 month duration range matches current guideline ranges (3-12 months depending on bleeding risk/ACS status).
Medication table uses only classes (DAPT, statins, beta blockers, ACE/ARB, nitrates, PCSK9 inhibitors), no specific drug names N/A Medication hard gate not triggered.

COPD Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Albuterol safety card (same as Asthma hub) FDA-approved albuterol prescribing information Card added to this hub independently since it must stand on its own.
Pulmonary rehab covered by Medicare for moderate-to-very-severe COPD Medicare.gov; 42 CFR 410.47 Confirmed accurate; Part B covers with standard 20% coinsurance + deductible, which the hub doesn’t overclaim as free.

Clinical Trial Resources Hub

Full audit pass completed September 13, 2026

Claim Source Notes
TrialX, CenterWatch, CISCRP, WHO ICTRP described as active, legitimate clinical trial search resources Direct verification of each organization’s current site/activity (trialx.com, centerwatch.com, ciscrp.org, WHO ICTRP) All four confirmed active and current as of September 2026.
No medications named on this hub N/A Medication hard gate not applicable.

FINDING — placeholder content: the hero section contains literal placeholder text (“[ Photo placeholder — swap in from SynquUp’s image library ]”) instead of a real image. This is a genuine violation of the “no placeholder content” requirement and needs a real photo supplied from Chuck’s asset library — this is a content asset gap, not something I can fabricate, and not a design/code change I should make unilaterally. Flagged as Needs Follow-Up.

Chronic Kidney Disease Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Ibuprofen and naproxen: FDA boxed warning (CV thrombotic events, GI bleeding), CABG contraindication, kidney-specific risk, urgent symptoms FDA-approved naproxen/ibuprofen prescribing information, accessdata.fda.gov Full safety card added, framed specifically around kidney risk since that’s the hub’s context for naming these drugs.
Medication table (ACE inhibitors/ARBs, SGLT2 inhibitors, diuretics, potassium binders, ESAs) General nephrology treatment classes No specific drug brand/generic names used in this table, only classes — hard gate not triggered for this table.

Caregiver Support Hub

Full audit pass completed September 13, 2026

Claim Source Notes
FMLA: 12 weeks/12-month period, 50+ employees within 75 miles, 12 months employed + 1,250 hours worked; military caregiver leave 26 weeks/single 12-month period U.S. Department of Labor, dol.gov/agencies/whd/fmla Confirmed accurate and current; no correction needed.
No medications named on this hub N/A Medication hard gate not applicable.

Asthma Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Montelukast (Singulair) mental-health boxed warning FDA Drug Safety Communication, March 4, 2020, “FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair)” Critical gap closed: hub previously described montelukast with no mention of this boxed warning at all. Full safety card added — this is a significant, under-recognized warning (82 completed-suicide case reports contributed to the FDA’s decision).
Albuterol: no boxed warning, but paradoxical bronchospasm, cardiovascular caution, hypokalemia/hyperglycemia risk, beta-blocker interaction, “excessive use may be fatal” warning FDA-approved albuterol/ProAir/Ventolin prescribing information, accessdata.fda.gov Full safety card added.

Aging Alone Hub

Full audit pass completed September 13, 2026

Claim Source Notes
Apple Watch fall detection: timing mechanism and default-on age threshold Apple official support documentation (support.apple.com) Corrected: hub previously said “30 seconds,” actual mechanism is ~1 minute immobile + 30-second countdown (~90 seconds total). Added that it’s on by default for age 55+.
HHS estimate that ~70% of people who reach 65 will need long-term care HHS/ASPE long-term care projections (previously verified on Home Health/Hospice hub, same claim) Confirmed accurate; consistent across hubs.
Credit freeze process (3 bureaus: Equifax, Experian, TransUnion, separately) Standard, well-established consumer protection process Accurate; no correction needed.
No medications named on this hub N/A Medication hard gate not applicable to this hub.

AFib Hub

Medication hard-gate pass completed September 13, 2026

Claim Source Notes
Eliquis (apixaban): boxed warnings (early discontinuation, spinal/epidural hematoma), indication, contraindications, common adverse reactions, interactions, reversal agent FDA-approved Eliquis prescribing information, accessdata.fda.gov Full medication safety card added to hub.
Xarelto (rivaroxaban): same boxed warnings, indication, contraindications, adverse reactions, reversal agent FDA-approved Xarelto prescribing information, accessdata.fda.gov Full medication safety card added.
Pradaxa (dabigatran): same boxed warnings plus specific mechanical heart valve contraindication (RE-ALIGN trial), reversal agent FDA-approved Pradaxa prescribing information, accessdata.fda.gov Full medication safety card added.
Savaysa (edoxaban): same boxed warnings plus third boxed warning for reduced efficacy at CrCL >95 mL/min (ENGAGE AF-TIMI 48 trial) FDA-approved Savaysa prescribing information, accessdata.fda.gov Full medication safety card added.
Warfarin (Jantoven; Coumadin discontinued 2020): boxed warning for major/fatal bleeding, INR monitoring requirement, diet/interaction sensitivity, pregnancy warning FDA-approved Coumadin/warfarin prescribing information, accessdata.fda.gov; DailyMed Full medication safety card added; confirmed Coumadin brand discontinued April 2020, current brand is Jantoven.
Watchman device described as for “patients with high bleeding risk who can’t take anticoagulants long-term” Original 2015 FDA approval labeling (Boston Scientific); TCTMD, Healio coverage Minor nuance: original labeling required patients be “deemed suitable for warfarin” but seeking a non-drug alternative, not literally unable to take anticoagulants. Hub’s framing is a reasonable patient-facing simplification reflecting how eligibility criteria have broadened in practice, not a false claim; left as-is.

Last checked: September 12, 2026

Claim Source Notes
Anticoagulation (DOACs and warfarin), rate control (beta blockers, calcium channel blockers), rhythm control (antiarrhythmics, cardioversion, catheter ablation), and left atrial appendage occlusion (Watchman) as treatment categories 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation, Circulation, published November 30, 2023 (doi: 10.1161/CIR.0000000000001193) — professional.heart.org Current U.S. clinical standard, updating the 2014/2019 guidelines. LAAO devices were upgraded to a Class 2a recommendation in this version for patients with a contraindication to long-term anticoagulation.
FAST stroke warning signs (Face, Arm, Speech, Time) American Stroke Association / CDC, standard public stroke-recognition framework — stroke.org Widely adopted U.S. public-health messaging; used here because AFib is a major stroke risk factor.

Aging Alone Hub

Last checked: September 12, 2026

Claim Source Notes
Roughly 70% of people who reach age 65 will need some form of long-term care during their lifetime U.S. Department of Health and Human Services, Administration for Community Living / ASPE, “How Much Care Will You Need?” — acl.gov Standard, widely-cited federal long-term-care planning statistic; used consistently across SynquUp’s aging and long-term-care hubs.
Credit freezes at all three bureaus (Equifax, Experian, TransUnion) are free and prevent new credit from being opened in your name Federal Trade Commission, “Credit Freeze FAQs” — consumer.ftc.gov Confirms freezes must be placed separately at each bureau and are free under federal law.
Adult Protective Services handles suspected financial exploitation of older adults; state Attorneys General handle consumer fraud complaints National Adult Protective Services Association — napsa-now.org; National Association of Attorneys General — naag.org Standard referral pathways for elder-fraud reporting.

Chronic Kidney Disease Hub

Last checked: September 12, 2026

Claim Source Notes
ACE inhibitors/ARBs and SGLT2 inhibitors as first-line, kidney-protective therapy; NSAID caution; renal dietitian and multidisciplinary care team roles KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease — kdigo.org Current international standard, updated 2024. SGLT2 inhibitors are now recommended for CKD patients with eGFR ≥20 mL/min/1.73m², with or without diabetes, combined with maximally tolerated ACEi/ARB therapy.

Clinical Trial Resources Hub

Last checked: September 12, 2026

Claim Source Notes
Sponsored featured trial listings may only state condition, trial type, phase, and eligibility contact — never safety or efficacy claims FDA, 21 CFR 312.7(d) (promotion of investigational drugs); FTC paid-placement disclosure guidance Sponsor-placement language explicitly scoped to this standard; no sponsor is currently active on this hub.
Trial participants still receive standard care in most trials; participation is voluntary and requires informed consent National Cancer Institute, “What Are Clinical Trials?” — cancer.gov General clinical-trials education, applied here across conditions, not only oncology.
Directory resources: ClinicalTrials.gov, National Cancer Institute, TrialX, CenterWatch, CISCRP, WHO ICTRP Each organization’s own site, linked directly from this hub Independently selected, non-sponsored directory listings; ClinicalTrials.gov is queried live via its public API.

Coronary Artery Disease Hub

Last checked: September 12, 2026

Claim Source Notes
Dual antiplatelet therapy (DAPT) duration after drug-eluting stent placement, and the risk of stent thrombosis from early discontinuation Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease. Circulation. 2016;134(10):e123-155 — ahajournals.org Still the operative U.S. guideline on DAPT duration; recommends never stopping DAPT early without cardiology guidance, exactly as framed on this hub.
Statins, beta blockers, ACE inhibitors/ARBs, and cardiac rehab as standard secondary-prevention therapy after a coronary event 2018 ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol; 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization Standard secondary-prevention framework; cardiac rehab referral is a Medicare-covered benefit for qualifying diagnoses.

COPD Hub

Last checked: September 12, 2026

Claim Source Notes
Bronchodilator (LAMA/LABA) and inhaled corticosteroid treatment tiers; early flare-up recognition and action-plan framing; pulmonary rehab as a Medicare-covered, protective intervention Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2026 Global Strategy for Prevention, Diagnosis and Management of COPD — goldcopd.org GOLD is the internationally recognized, annually updated clinical standard for COPD management.
Inhaler technique errors are common and reduce effective medication delivery American Lung Association / American Thoracic Society patient education materials on inhaler technique Well-established clinical teaching point; used here to support the “ask your pharmacist to watch you use it” guidance.

Dementia Hub

Last checked: September 12, 2026

Claim Source Notes
Cholinesterase inhibitors, memantine, disease-modifying therapies, and non-drug approaches (behavioral therapy, cognitive stimulation, physical activity) as treatment categories National Institute on Aging, “How Is Alzheimer’s Disease Treated?” — nia.nih.gov NIA is the primary federal patient-education source on dementia treatment; disease-modifying therapies require confirmed amyloid-positive diagnosis and ongoing monitoring per current FDA labeling.
Alzheimer’s Association 24/7 Helpline (1-800-272-3900) Alzheimer’s Association — alz.org Free, confidential, available in over 200 languages via translation service.

Diabetes Hub

Last checked: September 12, 2026

Claim Source Notes
Metformin as first-line Type 2 therapy; GLP-1/GIP-GLP-1 agonists, SGLT2 inhibitors, sulfonylureas, and insulin as treatment categories; annual dilated eye and foot exams; DSME (diabetes self-management education) as an underused, effective, insurance-covered benefit American Diabetes Association, Standards of Care in Diabetes — 2026 — diabetesjournals.org Annually updated U.S. clinical standard. DSME/DSMES is a Medicare Part B covered benefit when referred by a physician.
FDA Boxed Warning on GLP-1/GIP-GLP-1 medications — rodent thyroid C-cell tumor risk, contraindicated with personal/family MTC or MEN 2 history FDA-approved prescribing information for semaglutide- and tirzepatide-containing medications Quoted directly from labeling language, as noted on the hub itself.

Emergency Readiness Hub

Last checked: September 12, 2026

Claim Source Notes
EMTALA (1986) requires Medicare-participating hospital EDs to screen and stabilize anyone with a possible emergency regardless of insurance or ability to pay, but does not guarantee free care, and some standalone for-profit EDs opt out of Medicare specifically to avoid EMTALA CMS, “Emergency Medical Treatment & Labor Act (EMTALA)” — cms.gov Verified current; the non-Medicare-participating freestanding ED phenomenon is a documented, ongoing consumer-protection gap distinct from EMTALA itself.
Utilities often maintain a “medical priority” or “critical care” list for customers with powered medical equipment, providing outage notice and restoration priority Standard utility consumer-protection program, offered by most major U.S. electric utilities (verify with local utility for exact terms) Practice varies by utility; hub frames this as “ask your utility,” not a guaranteed universal program.

Falls & Frailty Hub

Last checked: September 12, 2026

Claim Source Notes
Fall-risk screening factors (history of falls, unsteadiness, fear of falling, polypharmacy) and about 1 in 4 adults 65+ falling each year CDC, STEADI (Stopping Elderly Accidents, Deaths & Injuries) Initiative — cdc.gov/steadi STEADI is the CDC’s clinical fall-prevention framework; the hub’s quick-check quiz is explicitly modeled on it.
National Falls Prevention Awareness Week, September 21–25, 2026, led by the National Council on Aging National Council on Aging — ncoa.org Annual observance, timed to the first day of autumn.
Resistance training, balance training (including Tai Chi), home modifications, medication review, and vision correction as evidence-based fall-prevention interventions CDC STEADI clinical resources; American Geriatrics Society/British Geriatrics Society Clinical Practice Guideline for Prevention of Falls in Older Persons Standard multifactorial fall-prevention framework.

Food, Housing and Daily Help Hub

Last checked: September 12, 2026

Claim Source Notes
211 as a free, confidential referral service for local emergency and social-service needs United Way, 211.org — 211.org Nationwide referral network, no eligibility screening required to call.
National Domestic Violence Hotline (1-800-799-7233, text START to 88788) National Domestic Violence Hotline — thehotline.org Free, confidential, 24/7.
Community health centers, WIC, and school meal programs serve everyone regardless of immigration status, without requiring proof of status for emergency care HRSA, Health Center Program requirements; USDA, WIC and National School Lunch Program eligibility rules Federally Qualified Health Centers and USDA child nutrition programs do not condition basic eligibility on immigration status.

Heart Failure Hub

Last checked: September 12, 2026

Claim Source Notes
The four-drug-class “pillars” of guideline-directed medical therapy (ACE/ARB/ARNI, beta blockers, MRAs, SGLT2 inhibitors) as life-extending, not just symptomatic; diuretics for fluid management; daily weight monitoring and zone-based (green/yellow/red) symptom tracking 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure — ahajournals.org Current U.S. guideline; SGLT2 inhibitors were added as a fourth foundational pillar in this version, matching the hub’s framing.

High Blood Pressure Hub

Last checked: September 12, 2026

Claim Source Notes
Blood pressure categories (Normal, Elevated, Stage 1, Stage 2, Hypertensive Crisis at ≥180/≥120) and first-line medication classes (ACE inhibitors, ARBs, thiazide diuretics, calcium channel blockers) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults — ahajournals.org Still the current comprehensive U.S. guideline; the interactive category checker on this hub matches these thresholds exactly.
Home blood pressure monitoring gives a fuller picture than a single office reading American Heart Association, “Monitoring Your Blood Pressure at Home” — heart.org Standard AHA patient guidance.

HIV & PrEP Care Hub

Last checked: September 12, 2026

Claim Source Notes
PrEP reduces HIV risk from sex by about 99% and from injection drug use by at least 74% when taken as prescribed CDC, “PrEP Effectiveness” — cdc.gov; NIH HIVinfo — hivinfo.nih.gov Verified current CDC figures, matched exactly on this hub.
U=U (undetectable = untransmittable) — people with HIV on effective treatment with an undetectable viral load cannot sexually transmit the virus CDC, “Evidence of HIV Treatment and Viral Suppression in Preventing Sexual Transmission of HIV” — cdc.gov Well-established, evidence-based public health message.
Ryan White Program, ADAP, and FQHCs as low/no-cost care pathways regardless of insurance or immigration status Health Resources & Services Administration, Ryan White HIV/AIDS Program — ryanwhite.hrsa.gov Federal program descriptions accurate as stated.

Note: this hub gives MISTR a visually distinct, bordered featured placement not given to other listed resources (NIH, CDC, hiv.gov), while the section header states resources are “not part of any sponsored placement.” Worth confirming with Chuck whether MISTR is an actual sponsor requiring disclosure, or whether the featured styling should be normalized to match the other resource listings.

Home Health, Hospice and Palliative Care Hub (updated, still draft)

Last checked: September 12, 2026

Claim Source Notes
Homebound test, skilled-care requirement, and the “no improvement required” rule for home health and SNF coverage CMS Medicare Benefit Policy Manual; Jimmo v. Sebelius settlement (2013) The improvement-standard myth is confirmed still an active, ongoing problem per Center for Medicare Advocacy tracking, not just a historical footnote.
Assisted living: Medicare never covers room/board; 44 states cover some services via Medicaid waiver as of 2025; ~80% paid privately nationally Genworth Cost of Care Survey; state Medicaid waiver program data compiled by AARP Public Policy Institute Figures are directionally solid; exact state counts and percentages shift year to year and are worth a periodic recheck.
Nursing home Medicaid estate recovery, home exemption while a spouse lives there, and the 5-year look-back period Medicaid.gov, Estate Recovery rules; CMS spousal impoverishment guidance State-by-state variation is real; hub correctly frames this as a reason to consult an elder law attorney rather than giving definitive answers.
VA Aid & Attendance eligibility (90 days active duty, one day wartime, ADL need, net worth limit) U.S. Department of Veterans Affairs, Aid and Attendance and Housebound benefits — va.gov Verified current program structure.

Mental Health Hub

Last checked: September 12, 2026

Claim Source Notes
988 Suicide & Crisis Lifeline (call/text), Veterans Crisis Line (988, press 1), Crisis Text Line (741741) SAMHSA, 988 Suicide & Crisis Lifeline — 988lifeline.org Verified current numbers and routing.
FDA boxed warning: antidepressants increase risk of suicidal thinking and behavior in short-term studies in children, adolescents, and young adults FDA class labeling for antidepressant medications Quoted as worded in FDA-mandated labeling, as the hub itself states.
Asking directly about suicide does not increase risk Dazzi et al., “Does asking about suicide and related behaviours induce suicidal ideation? What is the evidence?” Psychological Medicine (2014); consistent with subsequent research reviews Well-replicated finding in suicide-prevention research.
Postpartum psychosis is a medical emergency American College of Obstetricians and Gynecologists (ACOG); Postpartum Support International Standard clinical consensus.

Obesity & GLP-1 Hub

Last checked: September 12, 2026

Claim Source Notes
FDA Boxed Warning on GLP-1 medications (rodent thyroid C-cell tumor risk, MTC/MEN 2 contraindication) FDA-approved prescribing information for Wegovy (semaglutide) and Zepbound (tirzepatide) Quoted directly from labeling language, as the hub itself notes.
FDA safety/quality warnings on compounded semaglutide and tirzepatide products FDA, compounding safety communications on GLP-1 products — fda.gov Verified current FDA guidance distinguishing approved products from compounded versions.
National Alliance for Eating Disorders helpline (1-866-662-1235) National Alliance for Eating Disorders — allianceforeatingdisorders.com Correct current referral — NEDA’s own helpline was permanently discontinued; this hub correctly uses the Alliance instead.

Pain Management & Functional Recovery Hub

Last checked: September 12, 2026

Claim Source Notes
Multimodal, non-opioid-first approach; opioid therapy considered only when benefits are expected to outweigh risks; never stop opioids abruptly without prescriber guidance; naloxone co-prescribing as standard practice CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (MMWR Recomm Rep. 2022;71(3):1-95) — cdc.gov Current national guideline. Hub correctly notes this guideline does not apply to cancer, sickle cell disease, or palliative/end-of-life pain.

Pneumonia Hub

Last checked: September 12, 2026

Claim Source Notes
5-14 day typical antibiotic course, importance of completing the full course, and recovery warning signs (persistent/new fever, worsening breathing, confusion) Metlay JP, et al. 2019 American Thoracic Society/Infectious Diseases Society of America Clinical Practice Guideline for Community-Acquired Pneumonia in Adults — atsjournals.org Current joint ATS/IDSA guideline; typical duration is a minimum of 5 days per the guideline, with continuation until clinical stability, generally landing in the 5-7 day range for most outpatient cases and longer for complicated or hospitalized cases.
Pneumococcal and flu vaccines reduce risk of recurrent pneumonia CDC, pneumococcal and influenza vaccination recommendations — cdc.gov Standard preventive guidance.

Post-Discharge Recovery Hub

Last checked: September 12, 2026

Claim Source Notes
A follow-up visit within 7 days of discharge is one of the strongest predictors of avoiding readmission Agency for Healthcare Research and Quality (AHRQ), hospital readmission reduction literature; CMS Hospital Readmissions Reduction Program materials Widely supported in health-services research; framed here as general guidance, not a guarantee.
Medication reconciliation (“brown bag” review) after discharge meaningfully reduces adverse drug events and readmission risk The Joint Commission, National Patient Safety Goals on medication reconciliation; AHRQ patient safety resources Standard hospital patient-safety practice.

Preventive Care Hub

Last checked: September 12, 2026

Claim Source Notes
Full screening table (cancer, cardiometabolic, infectious disease, mental health/substance use, other services) and no-cost-sharing coverage under the ACA U.S. Preventive Services Task Force, current “A” and “B” grade recommendations — uspreventiveservicestaskforce.org Ages and intervals shown match current USPSTF recommendations, consistent with citations already verified for the Oncology hub’s screening section. NCCN higher-risk guidance is separately and correctly cited inline on this hub.
Adult vaccine schedule (flu, Tdap, Shingrix, pneumococcal, RSV, HPV, hepatitis A/B, MMR, varicella) and current ages/intervals CDC Advisory Committee on Immunization Practices (ACIP), Adult Immunization Schedule — cdc.gov Hub correctly flags RSV and COVID-19 guidance as recently changed and subject to further change — appropriately hedged rather than stated as fixed.
Medicare Annual Wellness Visit as a distinct, no-cost benefit separate from a regular physical Medicare.gov, “Yearly Wellness Visits” — medicare.gov Verified current.

Stroke and TIA Recovery Hub

Last checked: September 12, 2026

Claim Source Notes
FAST (Face, Arm, Speech, Time) stroke warning signs; secondary prevention with antiplatelets/anticoagulants (stroke-type-dependent), high-intensity statins, and blood pressure control Kleindorfer DO, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack, American Heart Association/American Stroke Association — ahajournals.org; CDC/American Stroke Association FAST campaign Current secondary-prevention guideline; hub correctly notes that anticoagulant vs. antiplatelet choice depends on stroke type/etiology.

UTI & Recurrent Infections Hub

Last checked: September 12, 2026

Claim Source Notes
First-line vs. second-line antibiotic selection, prophylactic antibiotics and vaginal estrogen for recurrent UTI, and phenazopyridine as symptomatic-only relief Gupta K, et al. IDSA/ESCMID International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis; American Urological Association, Recurrent Uncomplicated UTI Guideline Current joint infectious-disease/urology guidance.
FDA Boxed Warning on fluoroquinolone antibiotics (tendon, nerve, CNS, myasthenia gravis risks) FDA-approved prescribing information for ciprofloxacin and related fluoroquinolones Quoted directly from labeling language, as the hub itself notes.

Osteoarthritis Hub (new, draft)

Last checked: September 11, 2026

Claim Source Notes
Exercise, weight loss, and self-management as strongly recommended first-line therapy American College of Rheumatology / Arthritis Foundation, 2019 Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (2020 update) Strong recommendations for exercise (all OA), weight loss (overweight/obese with knee or hip OA), and self-efficacy/self-management programs.
Topical NSAIDs, oral NSAIDs, and intra-articular glucocorticoid injections for knee OA Same ACR/Arthritis Foundation guideline All strongly or conditionally recommended per the guideline; framed here as options to discuss, not defaults.
Hyaluronic acid (“gel”) injections, PRP, and stem cell injections are not currently recommended Same ACR/Arthritis Foundation guideline Guideline suggests against these due to insufficient evidence of benefit — included so patients can ask informed questions if one is proposed.
Weight loss target (5%+ of body weight for BMI >25) and low-impact aerobic exercise American Academy of Orthopaedic Surgeons (AAOS), Clinical Practice Guideline on OA of the Knee, 3rd edition (2021) Physical therapy benefit shown to persist for months after a supervised program ends.

Caregiver Support Hub

Last checked: September 12, 2026

Claim Source Notes
FMLA eligibility and duration (12 weeks unpaid, 50+ employee employer, 12 months/1,250 hours worked; 26 weeks military caregiver leave) U.S. Department of Labor, Family and Medical Leave Act — dol.gov/agencies/whd/fmla Federal minimum; state paid family leave varies and is noted as such rather than detailed per state.
Caregiver burnout signs and respite care framing Family Caregiver Alliance — caregiver.org Used for the burnout check-in questions and general framing; not a diagnostic tool.

Disability Rights (ADA) & Disability Income Pages

Last checked: September 12, 2026

Claim Source Notes
ADA reasonable accommodation examples, interactive process, and undue hardship standard EEOC, Enforcement Guidance on Reasonable Accommodation and Undue Hardship Under the ADA — eeoc.gov Includes the “significant difficulty or expense” undue-hardship standard and the indefinite-leave exception.
SSDI vs. SSI eligibility, funding source, and Medicare/Medicaid timing Social Security Administration — ssa.gov/benefits/disability and ssa.gov/ssi Specific dollar benefit amounts deliberately omitted from the page since they change most years with COLA adjustments — page points to ssa.gov for current figures instead.

Medication Management and Safety Hub

Last checked: September 12, 2026

Claim Source Notes
Safe medication disposal methods and FDA flush list examples FDA, “Drug Disposal: FDA’s Flush List for Certain Medicines” — fda.gov; DEA National Prescription Drug Take Back Day — dea.gov/takebackday Flush-list examples shown (fentanyl, buprenorphine, hydrocodone, morphine, oxycodone, diazepam) are illustrative, not exhaustive — page directs to the current FDA list for any specific medication.
Generic medications must match brand-name active ingredient, strength, and effect FDA generic drug requirements (standard regulatory fact) General statement; narrow-therapeutic-index exceptions noted per standard pharmacy practice.

DME, Home Safety and Rehabilitation Hub

Last checked: September 12, 2026

Claim Source Notes
Medicare Part B DME coverage criteria (durable, 3+ year expected life, home use, doctor’s prescription, participating supplier, 80/20 cost split after deductible) Medicare.gov, “Durable Medical Equipment (DME) Coverage” — medicare.gov Specific deductible dollar amounts deliberately omitted since they change annually — page points to medicare.gov for current figures.

Healthcare Costs and Financial Assistance Hub

Last checked: September 12, 2026

Claim Source Notes
Nonprofit hospital financial assistance policy requirements (written policy, charge limits, collection-action limits) IRS, Section 501(r) of the Internal Revenue Code — irs.gov Verified current; applies to 501(c)(3) nonprofit hospitals, not for-profit hospitals specifically.
No current federal ban on medical debt appearing on credit reports; CFPB’s 2025 rule was vacated in court CFPB final rule (January 2025), vacated by U.S. District Court for the Eastern District of Texas, July 11, 2025 (joint request by CFPB and industry plaintiffs) This is a claim that changed materially within the last 18 months — verified as of September 2026 that the federal ban never took effect and was formally vacated, not merely delayed.
Voluntary credit bureau protections: paid medical debt removed entirely, debt under $500 generally not reported, ~12-month reporting delay on new medical debt Equifax, Experian, and TransUnion’s 2022–2023 voluntary policy changes (independent of the vacated CFPB rule) These predate and are unaffected by the CFPB rule’s vacatur — they remain the actual operative protection as of this writing.

Home Health, Hospice and Palliative Care Hub (draft, pending clinical review)

Last checked: September 12, 2026

Claim Source Notes
Hospice eligibility: Medicare Part A, 6-month terminal prognosis, physician certification, benefit-period structure (two 90-day periods then unlimited 60-day periods) CMS, Medicare Benefit Policy Manual (Pub. 100-02), Chapter 9, Section 20.1 — cms.gov Verified current as of the March 2026 CMS transmittal (effective Oct 1, 2025) covering certification, revocation, and discharge guidance.
Patients can revoke hospice election at any time and return to regular Medicare-covered treatment, and re-elect hospice later if still eligible Same CMS manual, Section 20.2.2 (Hospice Revocation) This is the single fact on this hub most likely to be misunderstood if omitted — verified directly against the current CMS manual, not a secondary source.
Discharge for extended prognosis: hospice-initiated discharge when a patient’s condition stabilizes/improves beyond the 6-month standard, distinct from patient-initiated revocation; requires physician discharge order and planning; patient has appeal rights to a QIO CMS Medicare Benefit Policy Manual Ch. 9; NHPCO, “Managing Live Patient Discharge in Hospice Care” toolkit (nhpco.org) Added per user’s direct question about patients improving and no longer meeting the 6-month rule — this is a distinct mechanism from voluntary revocation, and the page previously only implied it through the recertification language rather than naming it directly.
Palliative care is available at any stage of serious illness and can be received alongside curative treatment; distinct from hospice Center to Advance Palliative Care (CAPC) and National Hospice and Palliative Care Organization (NHPCO) Standard, uncontested distinction in the palliative medicine field.

This hub is in draft, held for clinical review before publication, per the elevated stakes of getting hospice eligibility rules right.

Insurance and Medicare Hub — corrections from external audit review

Last checked: September 12, 2026

Claim Source Notes
ACA “subsidy cliff” status for 2026 coverage (enhanced subsidies expired end of 2025, cliff restored at 400% FPL) KFF, “A Steep Subsidy Cliff Looms for Older Middle-Income Enrollees” (Oct 2025); confirmed current as of Jan 1, 2026 expiration An external audit flagged the site’s prior vague “subsidy cliff” language as possibly outdated. Verified the opposite: the cliff is genuinely back and the claim needed to become MORE specific and urgent, not softened. 400% FPL figures ($62,600 single / $128,600 family of four) are 2026 marketplace figures and will change annually.
Hospital financial assistance requirement applies specifically to nonprofit hospitals (IRC 501(r)), not all hospitals IRS, Section 501(r) Corrected an overbroad claim per external audit review; matches the citation already on the Healthcare Costs & Financial Assistance hub.
“Insurance language is confusing by design” / “confusing on purpose” N/A — removed as an unsupported claim of intent Softened to “often complex and difficult to compare” per external audit review; no source asserts insurers deliberately design confusing language, so the claim was removed rather than sourced.

Have a question about a source, or think something here is out of date? Contact SynquUp using the details on our Contact Us page.